Suzhou Ribo Life Science
-
Conshohocken’s Madrigal Makes $4B Bet on the Future of Liver Disease Treatment
Conshohocken’s Madrigal Pharmaceuticals is making a major move that could reshape the future of liver disease treatment, writes John George for The Philadelphia Business Journal.…
Founding Partners
Advertisement
Affiliate Partners
